i believe the reciepts from customers ($243065) is the culmulative figure since IPO, being an increase of$14962 over the August report. so nothing to be excited about, but not unexpected.
Personally i am not fixating on the 'other uses' outside of pregancy, as there are other companies that are in the space or plan to be (eg, see CDX -disclosure, on watchlist but i currently dont hold). What the Herabeat device currently does represents enough of a opportunity and it is likely the use cases will be expanded in the pregancy realm, i.e in this announcement 'Mayo clinic trial to expand FDA indications'; and in the latest investor presentation it notes trials and commercialization of monitoring high risk patients.
It was good to see mention of other global collaborations. In the latest investor presenation these were not mentioned at all and i was thinking it was a subtle tell that these had been written off.
Direct to customer (D2C) still looks on the cards which really dont see as a significant opportunity. On a related note, the Herabeat device is currently offered on the website as a 14 day trial and $100 off purchase.
Cash burn increased with trials this qtr, must be CR next qtr to stay afloat? I am expecting a busy end to the year, feels like it needs to be.
- Forums
- ASX - By Stock
- HMD
- Ann: Quarterly Activities & Cashflow Report
Ann: Quarterly Activities & Cashflow Report, page-33
-
-
- There are more pages in this discussion • 19 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add HMD (ASX) to my watchlist
(20min delay)
|
|||||
Last
2.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $15.83M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 76923 | 2.6¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
2.6¢ | 406429 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 76923 | 0.026 |
1 | 21250 | 0.024 |
3 | 1109214 | 0.015 |
1 | 200000 | 0.014 |
1 | 500000 | 0.013 |
Price($) | Vol. | No. |
---|---|---|
0.026 | 406429 | 2 |
0.027 | 329785 | 3 |
0.028 | 150000 | 1 |
0.031 | 1000 | 1 |
0.070 | 100000 | 1 |
Last trade - 10.47am 21/10/2024 (20 minute delay) ? |
Featured News
HMD (ASX) Chart |
Day chart unavailable
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, Chief Executive Officer
Paul Long
Chief Executive Officer
SPONSORED BY The Market Online